Note: Not all species have been tested for usefulness with this product. Only those species listed have been tested. We cannot make any guarantees about additional reactivities which may or may not occur.
This antibody is specific for the N Terminus Region of the target protein.
Species Reactivity:
Human.
Applications:
Uses:
This product has been QC tested in ELISA against recombinant protein only. The concentration for this product is lot dependent. Check product vial for current lot concentration. Typically concentration ranges from 0.5 to 1.5 mg/ml.
Dilutions:
ELISA, Immunohistochemistry-Paraffin 1:250-1:2000, Western Blot 1:5000-1:20000
Unit Size:
0.05 mg
Concentration:
Please see the vial label for concentration.
Notes:
Manufactured by SDIX's proprietary Genomic Antibody Technology™. GAT FAQs.
Packaging:
Storage:
Store at -20 °C. Avoid freeze-thaw cycles.
Buffer:
20 mM Potassium Phosphate, 150 mM Sodium Chloride, pH 7.0
Preservative:
No Preservative
Limitations:
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Products are guaranteed for 6 months from date of receipt, except for peptides and proteins which are guaranteed for 3 months.
This gene encodes a member of the IGF-II mRNA-binding protein (IMP) family. The protein encoded by this gene contains several four KH domains and two RRM domains. It functions by binding to the 5' UTR of the insulin-like growth factor 2 (IGF2) mRNA and regulating IGF2 translation. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq]
Immunohistochemistry: IGF2BP2 Antibody [23750002] - Both normal and malignant tissues showed moderate to strong cytoplasmic staining. In normal tissues, surface epithelial cells of bronchus, glandular cells of the intestine, endometrium and cervix, and trophoblastic cells displayed strong cytoplasmic staining. Pancreas, surface epithelial cells of oral mucosa, vagina and cervix, non-neuronal cells of CNS tissues and lymphoid tissues were negative. Colo-rectal, skin and testis carcinomas exhibited strong cytoplasmic staining while ovarian, stomach and pancreas malignancies displayed moderate to strong cytoplasmic staining. Malignant carcinoids showed weak cytoplasmic and nuclear staining. Renal and prostate malignancies were weak to negative. Image and statement courtesy of the Human Protein Atlas (HPA).
Western Blot: IGF2BP2 Antibody [23750002] - Samples: Lane 1, Marker [kDa]: 250, 130, 95, 72, 55, 36, 28, 17, 11 Lane 2, RT-4 Lane 3, U-251MG sp Lane 4, Human Plasma Lane 5, Liver Lane 6, Tonsil Target weight [kDa]: 66, 62 (splice variants) Validation score: 2 Validation description: Supportive - Band of predicted size in kDa (+/-20%) with additional bands present.